Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

Abstract Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patien...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas, Stefan Rieken
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMC 2019-11-01
Serie:BMC Cancer
Soggetti:
Non-small cell lung cancer
Immunotherapy
Radioimmunotherapy
Abscopal effect
PD-1
Nivolumab
Accesso online:http://link.springer.com/article/10.1186/s12885-019-6205-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi